Brian Farah, MD
Psychiatry · Winston Salem, NCNPI 1174552079
Payments from drug & device makers
Across 821 payments — averaging $736.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$198K
- Neurocrine Biosciences, Inc.$153K
- E.r. Squibb & Sons, L.L.C.$118K
- Alkermes, Inc.$82K
- Teva Pharmaceuticals USA, Inc.$29K
- Idorsia Pharmaceuticals US Inc$21K
- plus $4K from 7 others
What the payments were for
- Consulting fees$44,0677%
- Speaking & faculty fees$508,94784%
- Travel & lodging$36,9976%
- Food & beverage$15,0532%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 207 | $198,139 |
| Neurocrine Biosciences, Inc. | 213 | $153,036 |
| E.r. Squibb & Sons, L.L.C. | 143 | $118,470 |
| Alkermes, Inc. | 141 | $81,912 |
| Teva Pharmaceuticals USA, Inc. | 43 | $28,601 |
| Idorsia Pharmaceuticals US Inc | 27 | $21,320 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $2,641 |
| Johnson & Johnson | 12 | $433 |
| Lundbeck LLC | 17 | $344 |
| Axsome Therapeutics, Inc. | 3 | $69 |
| Janssen Scientific Affairs, LLC | 1 | $69 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Indivior Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$315,951
- ABILIFY MAINTENA$195,060
- INGREZZA$149,573
- COBENFY$105,699
- ARISTADA INITIO$78,988
- ABILIFY ASIMTUFII$77,919
- UZEDY$27,743
- QUVIVIQ$20,922
- CAPLYTA$2,250
- LYBALVI$901
- SPRAVATO$125
- NUEDEXTA$122
- INVEGA SUSTENNA$120
- INVEGA TRINZA$120
- AUSTEDO$116
- REXULTI$111
How this compares
$605,063 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 62 | $193,972 |
| AristadaAripiprazole Lauroxil | 61 | $193,949 |
| Abilify MaintenaAripiprazole | 53 | $142,960 |
| Invega TrinzaPaliperidone Palmitate | 18 | $139,113 |
| PerserisRisperidone | 11 | $29,977 |
| Risperdal ConstaRisperidone Microspheres | 13 | $28,265 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $15,391 |
| Clozapine | 120 | $7,277 |
| Fluphenazine Hcl | 44 | $4,247 |
| Paliperidone ErPaliperidone | 28 | $2,866 |
| Chlorpromazine Hcl | 26 | $1,963 |
| Benztropine Mesylate | 127 | $1,739 |
| Aripiprazole | 51 | $1,452 |
| Fluphenazine Decanoate | 13 | $1,307 |
| Gabapentin | 74 | $1,107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $433 | $361,34993 claims |
| Alkermes, Inc.Aristada, Lybalvi | $81,912 | $209,34172 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $198,139 | $142,96053 claims |
| Indivior Inc.Perseris | $13 | $29,97711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Winston Salem
- Ruth BencaWinston Salem$521K
- Richard JacksonWinston Salem$92K
- Adam McDonoughWinston Salem$69K
- Martha ShupingWinston Salem$67K
- Craig ChepkeHuntersville$4.1M
- James BarkerHickory$4.1M
- Mark ReynoldsDurham$3.2M
- Oleg TcheremissineCharlotte$2M
- Richard WeislerRaleigh$1.2M
- Dan BlazerDurham$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.